Actively Recruiting
Personalized DC Vaccine for Postoperative Cancer
Led by Sichuan University · Updated on 2025-02-28
80
Participants Needed
1
Research Sites
365 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.
CONDITIONS
Official Title
Personalized DC Vaccine for Postoperative Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants with a first diagnosis of gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, or colorectal cancer who have undergone curative resection or ablation
- Anticipated lifetime longer than 3 months
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ functions
You will not qualify if you...
- Any evidence of tumor metastasis or co-existing malignant disease
- Tumor emergency conditions
- Abnormal blood clotting conditions
- Contagious diseases such as hepatitis B virus, hepatitis C virus, human immunodeficiency virus, or tuberculosis infection
- Presence of other tumors
- Immunological co-morbidities
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qiu Li
Chengdu, Sichuan, China, 610041
Actively Recruiting
Research Team
Q
Qiu Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here